Avalon Ventures XI, L.P.
SEC CIK 1652901 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | 10% | 3.34M | $4.99M | $82.12M | 5 | 2023-11-13 | 2024-06-03 |
Most active insiders at JANX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Meyer Andrew Hollman | Chief Business Off | — | $736.7K |
| 2 | Campbell David Alan | Pres, CEO, Dir | — | $110.8K |
| 3 | Doyle Janeen Noel | Chief Corp, Bus. Dev. Ofcr | — | $56.9K |
| 4 | Dobek Maria | VP, Accounting | — | $49.0K |
| 5 | McIver Zachariah | Chief Medical Off | — | $37.3K |
| 6 | DiRaimondo Thomas | CSO | — | $34.4K |
| 7 | Winter Charles M. | Chief Technical Off | — | $33.0K |
| 8 | Go William | Chief Medical Off | — | — |
| 9 | Simson Jake | Dir | — | — |
| 10 | Hernday Natasha | Dir | — | — |
Avalon Ventures XI, L.P. made no open-market trades at JANX in the last 12 months.
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-06-05 | 2024-06-03 | JANX | Janux Therapeutics, Inc. | Avalon Ventures XI, L.P. | 10% | S - Sale | $54.75 | -822.7K | 3.34M | -20% | -$45.04M |
| 2024-06-05 | 2024-06-03 | JANX | Janux Therapeutics, Inc. | Avalon Ventures XI, L.P. | 10% | S - Sale | $54.75 | -677.3K | 3.27M | -17% | -$37.08M | |
| 2024-03-04 | 2024-02-29 | JANX | Janux Therapeutics, Inc. | Avalon Ventures XI, L.P. | 10% | J - Other | $0.00 | -438.7K | 3.95M | -10% | $0 | |
| MI | 2024-03-04 | 2024-02-29 | JANX | Janux Therapeutics, Inc. | Avalon Ventures XI, L.P. | 10% | J - Other | $0.00 | -532.9K | 4.03M | -12% | $0 |
| I | 2023-11-13 | 2023-11-13 | JANX | Janux Therapeutics, Inc. | Avalon Ventures XI, L.P. | 10% | P - Purchase | $5.87 | +849.9K | 849.9K | New | +$4.99M |
Purchase Sale Sale after option exercise All abbreviations